Singh KT1, Traiki TAB1*, Alzharani N1, Liauw W2 and Morris DL1
1Department of Surgery, University of New South Wales, Australia
2Department of Medical Oncology, University of New South Wales, Australia
Introduction: Rectal and rectosigmoidal carcinoma is traditionally treated with a combination of surgery and either adjuvant or neoadjuvant radiotherapy. Local peritoneal recurrence may be treated with cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC). Given the toxicity of radiotherapy and HIPEC on the bowel, we aim to determine post-operative outcomes of patients with combined treatment.Method: Our prospective database from 1996 to 2014 was searched for patients with radiotherapy and primary excision, followed by CRS and HIPEC. 5 patients were identified and analysed for postoperative complication and survival.Results: Survival post-CRS range from 11 to 45 months with 2 of the 5 patients still living. In the 3 patients that died, 2 had metastatic recurrence while 1 had recurrent post-HIPEC fistulae causing death.Conclusion: CRS and HIPEC after adjuvant or neoadjuvant radiotherapy for rectal carcinoma are associated with considerable morbidity but can also achieve relatively longer term survival compared to no CRS or HIPEC.
HIPEC; Cytoreductive surgery; Radiotherapy; Rectal carcinoma; Outcomes
Singh KT, Traiki TAB, Alzharani N, Liauw W, Morris DL. Outcomes of HIPEC and Cytoreductive Surgery Following Radiotherapy and Excision of Rectal Carcinoma. Clin Surg. 2016; 1: 1126.